FDA takes action on updated mRNA COVID-19 vaccines to better protect against currently circulating variants
|
11 September 2023 |
FDA approves first oral treatment for postpartum depression
|
07 August 2023 |
FDA approves first nonprescription daily oral contraceptive
|
13 July 2023 |
FDA approves first gene therapy for treatment of certain patients with Duchenne muscular dystrophy
|
22 June 2023 |
FDA announces additional steps to modernize clinical trials
|
06 June 2023 |
FDA approves first drug to treat agitation symptoms associated with dementia due to Alzheimer's disease
|
11 May 2023 |
FDA approves first respiratory syncytial virus (RSV) vaccine
|
04 May 2023 |
FDA approves cell therapy for patients with blood cancers to reduce risk of infection following stem cell transplantation
|
17 April 2023 |
FDA approves first over-the-counter naloxone nasal spray
|
29 March 2023 |
FDA grants Accelerated Approval for Alzheimer's disease treatment
|
06 January 2023 |
FDA approves new HIV drug for adults with limited treatment options
|
22 December 2022 |
FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
|
16 December 2022 |
FDA approves first gene therapy to treat adults with Hemophilia B
|
22 November 2022 |
FDA approves first treatment for Acid Sphingomyelinase Deficiency, a rare genetic disease
|
31 August 2022 |
FDA approves first systemic treatment for alopecia areata
|
13 June 2022 |
FDA urges drug manufacturers to develop risk management plans to promote a dtronger, resilient drug supply chain
|
19 May 2022 |
FDA limits use of Janssen COVID-19 vaccine to certain individuals
|
06 May 2022 |
FDA approves first generic of Symbicort to treat asthma and COPD
|
15 March 2022 |
FDA approves treatment for wider range of patients with heart failure
|
24 February 2022 |
FDA takes key action by approving second COVID-19 vaccine
|
31 January 2022 |